News Related to Alpha 1-Antitrypsin Deficiency

Related coverage linked through entity extraction aliases.

Krystal Biotech Reports Q4 Revenue of $107.1M, Expands International Presence

Mar 20, 2026

Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.

YolTech Therapeutics Receives FDA Clearance for Phase 2/3 Study of YOLT-202 in AATD

Mar 14, 2026

YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.